[go: up one dir, main page]

NO20076041L - Identifisering av HLA-A2-presenterte T-celleepitoper som er avledet fra onkofotalt antigen-umodent lamininreseptorprotein og anvendelser derav - Google Patents

Identifisering av HLA-A2-presenterte T-celleepitoper som er avledet fra onkofotalt antigen-umodent lamininreseptorprotein og anvendelser derav

Info

Publication number
NO20076041L
NO20076041L NO20076041A NO20076041A NO20076041L NO 20076041 L NO20076041 L NO 20076041L NO 20076041 A NO20076041 A NO 20076041A NO 20076041 A NO20076041 A NO 20076041A NO 20076041 L NO20076041 L NO 20076041L
Authority
NO
Norway
Prior art keywords
tumor
present
relates
laminin receptor
hla
Prior art date
Application number
NO20076041A
Other languages
English (en)
Inventor
Matthias Zeis
Original Assignee
Immatics Biotechologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechologies Gmbh filed Critical Immatics Biotechologies Gmbh
Publication of NO20076041L publication Critical patent/NO20076041L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Denne oppfinnelsen vedrører immunterapeutiske fremgangsmåter, og molekyler og celler til anvendelse innen immunterapeutiske fremgangsmåter. Spesielt er denne oppfinnelsen relatert til immunterapi av kreft, spesielt flere tumortyper inkludert ondartede hematologiske tilstander. Videre er denne oppfinnelsen relatert til tumorassosierte T-hjelper cellepeptidepitoper, alene eller i kombinasjon med andre tumorassosierte peptider, som fungerer som aktive farmasøytiske ingredienser til vaksinesammensetninger som stimulerer antitumorimmunresponser. Spesielt er denne oppfinnelsen relatert til to nye peptidsekvenser utviklet fra HLA klasse I eller II molekyler fra menneskelig onkoføtalt antigen-umoden lamininreseptorprotein (OFA/iLR) som kan brukes i vaksinepreparater for å frambringe antitumorimmunresponser.
NO20076041A 2005-04-26 2007-11-23 Identifisering av HLA-A2-presenterte T-celleepitoper som er avledet fra onkofotalt antigen-umodent lamininreseptorprotein og anvendelser derav NO20076041L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05009095A EP1717245B1 (en) 2005-04-26 2005-04-26 T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof
PCT/EP2006/003888 WO2006114307A1 (en) 2005-04-26 2006-04-26 T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof

Publications (1)

Publication Number Publication Date
NO20076041L true NO20076041L (no) 2007-11-23

Family

ID=34935739

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076041A NO20076041L (no) 2005-04-26 2007-11-23 Identifisering av HLA-A2-presenterte T-celleepitoper som er avledet fra onkofotalt antigen-umodent lamininreseptorprotein og anvendelser derav

Country Status (14)

Country Link
US (1) US7968097B2 (no)
EP (2) EP1717245B1 (no)
JP (1) JP4870751B2 (no)
CN (1) CN101166759B (no)
AT (1) ATE512160T1 (no)
AU (1) AU2006239505B2 (no)
BR (1) BRPI0610841A2 (no)
CA (1) CA2606088C (no)
EA (1) EA013598B1 (no)
ES (1) ES2367643T3 (no)
NO (1) NO20076041L (no)
NZ (1) NZ563432A (no)
UA (1) UA97092C2 (no)
WO (1) WO2006114307A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003258081A1 (en) * 2002-08-02 2004-02-23 South Alabama Medical Sciences Foundation Cancer vaccines containing epitopes of oncofetal antigen
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP2567707B1 (en) * 2007-07-27 2016-10-05 Immatics Biotechnologies GmbH Composition of tumour-associated peptides and related anti-cancer vaccine
ES2342506T3 (es) * 2008-04-30 2010-07-07 Immatics Biotechnologies Gmbh Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
CA2756789A1 (en) * 2009-03-26 2010-09-30 Quantum Immunologics, Inc. Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
CA2767595A1 (en) * 2009-07-09 2011-01-13 South Alabama Medical Science Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
WO2011024791A1 (ja) * 2009-08-25 2011-03-03 タカラバイオ株式会社 レチノイン酸存在下でのｔ細胞集団の製造方法
EP2330122A1 (en) * 2009-12-02 2011-06-08 Asklepios Kliniken Hamburg Gmbh OFA/iLRP derived modified peptide
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
KR20240162609A (ko) * 2017-04-10 2024-11-15 이매틱스 바이오테크놀로지스 게엠베하 암에 대한 면역요법에 사용하기 위한 펩티드 및 그 조합
WO2018224166A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
US20230002730A1 (en) * 2018-05-18 2023-01-05 Children's National Medical Center Improved targeted t-cell therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ290089A (en) 1994-07-27 1999-05-28 Queensland Inst Med Res Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines
WO1997026328A1 (en) 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
AU2003258081A1 (en) 2002-08-02 2004-02-23 South Alabama Medical Sciences Foundation Cancer vaccines containing epitopes of oncofetal antigen
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005017102A2 (en) * 2003-05-30 2005-02-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2006014579A2 (en) * 2004-07-08 2006-02-09 The Regents Of California Enhancing class i antigen presentation with synthetic sequences

Also Published As

Publication number Publication date
CA2606088C (en) 2015-05-26
EP1874810A1 (en) 2008-01-09
AU2006239505B2 (en) 2012-05-10
EA200702202A1 (ru) 2008-04-28
NZ563432A (en) 2010-11-26
JP2008538901A (ja) 2008-11-13
CN101166759A (zh) 2008-04-23
EA013598B1 (ru) 2010-06-30
CN101166759B (zh) 2012-09-05
ATE512160T1 (de) 2011-06-15
UA97092C2 (ru) 2012-01-10
US20090041794A1 (en) 2009-02-12
WO2006114307A1 (en) 2006-11-02
AU2006239505A1 (en) 2006-11-02
BRPI0610841A2 (pt) 2010-07-27
EP1717245A1 (en) 2006-11-02
US7968097B2 (en) 2011-06-28
EP1717245B1 (en) 2011-06-08
ES2367643T3 (es) 2011-11-07
CA2606088A1 (en) 2006-11-02
JP4870751B2 (ja) 2012-02-08

Similar Documents

Publication Publication Date Title
NO20076041L (no) Identifisering av HLA-A2-presenterte T-celleepitoper som er avledet fra onkofotalt antigen-umodent lamininreseptorprotein og anvendelser derav
EA200800677A1 (ru) Опухолеассоциированные пептиды, беспорядочно связывающиеся с молекулами класса ii человеческого лейкоцитарного антигена (hla)
EA200800676A1 (ru) Опухолеассоциированные пептиды, связывающиеся с молекулами человеческого лейкоцитарного антигена (hla) i или ii класса, и относящаяся к ним противораковая вакцина

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application